| Patient | Benjamin Franklin |
|---|---|
| Date of birth | 1950-01-17 |
| Identifiers | MRN HR-EN004-SYN; SSN (made up) 000-04-3318 |
| Document date | 2026-03-02 |
| Author | Lydia Penhallow, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Bladder stone with hematuria and obstructive voiding symptoms in a 76-year-old man with gout and stage 3a chronic kidney disease. Please confirm the diagnosis, remove the stone, look for its cause and for other sources of the bleeding, and advise on preventing recurrence. [S]
Urgency: Soon, within four weeks. [S]
Questions for the consultant:
Two months of an interrupted urinary stream, pain at the end of voiding, and pink urine after car journeys. Recurrent gout, with three flares in the past year in the right big toe. Non-contrast CT today: single 2.6 cm bladder stone of about 420 Hounsfield units, no kidney stones, no hydronephrosis, enlarged prostate. Urinalysis: pH 5.2 and 12 red cells per high-power field. Serum urate 9.1 mg/dL; creatinine 1.36 mg/dL, eGFR 54; IPSS 16. Today we stopped hydrochlorothiazide, started losartan 50 mg, allopurinol 100 mg, and colchicine 0.6 mg daily, and advised acetaminophen rather than NSAIDs for pain. Never smoker. Worked with hot-metal printing type when young; blood lead 3.1 µg/dL [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
4 later historical claims are omitted because they describe events after the index age. See the teaching note.
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Hydrochlorothiazide 25 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2019-05-06 to 2026-03-02 | stopped | S |
| Losartan 50 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-02 | active | S |
| Allopurinol 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-02 to 2026-03-30 | completed | S |
| Colchicine 0.6 mg oral tablet, one tablet by mouth daily for flare prophylaxis | One tablet by mouth daily | Oral route | 2026-03-02 to 2026-09-14 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain, no more than 3 g a day | Two tablets every 6 hours as needed; maximum 6 tablets a day | Oral route | 2026-03-02 | active | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Gout with recurrent flares, mostly in the right big toe, without tophi; synthetic modern diagnosis linked to his documented gout | active | confirmed | M1A.0710 | S — Synthetic modern diagnosis; his recurrent gout is documented in his own letters (D). |
| Bladder stone (2.6 cm, uric acid on analysis) with bladder outlet obstruction, removed by cystolitholapaxy; synthetic modern diagnosis linked to his documented stone | resolved | confirmed | N21.0 | S — Synthetic modern diagnosis confirmed by CT and cystoscopy; his stone is documented in his own letters (D), though its composition is not known. |
| Chronic kidney disease stage G3a A1 | active | confirmed | N18.31 | S — Synthetic diagnosis; no measure of kidney function from his lifetime exists. |
| Essential hypertension | active | confirmed | I10 | S — Synthetic diagnosis; no blood pressure from his lifetime exists. |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1724 | Occupational exposure to heated type metal as a compositor in London, with an obscure pain in the bones of the hand; he stopped heating the type | D (CLM-0002) |
| February 1727 (1726/7 Old Style) | Pleurisy that very nearly carried him off | D (CLM-0010) |
| 1735 | Severe pleurisy ending in an abscess of the left lung, with full recovery | D (CLM-0011) |
| October 22, 1780 | Gout attack at midnight, recorded in his Dialogue between Franklin and the Gout | D (CLM-0005) |
| Winter of 1780 to 1781 | Long and severe fit of gout through the winter, leaving him weakened | D (CLM-0006) |
| About 1781 | First symptoms of the calculous complaint (bladder stone) | D (CLM-0007) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| father | Died in 1744 at 89; no illness before his last; cause not recorded in the cited source | 89 | D (CLM-0012) |
| mother | Died in 1752 at 85; no illness before her last; cause not recorded in the cited source | 85 | D (CLM-0012) |
| natural son | Died in 1736 at four of smallpox | 4 | D (CLM-0013) |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-02 | Body height | 175 | cm | S |
| 2026-03-02 | Body weight | 96 | kg | S |
| 2026-03-02 | Body mass index (BMI) [Ratio] | 31.3 | kg/m2 | S |
| 2026-03-02 | Systolic blood pressure | 148 | mm[Hg] | S |
| 2026-03-02 | Diastolic blood pressure | 86 | mm[Hg] | S |
| 2026-03-02 | Heart rate | 74 | /min | S |
| 2026-03-02 | Respiratory rate | 16 | /min | S |
| 2026-03-02 | Body temperature | 36.7 | Cel | S |
| 2026-03-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-02 | Urate [Mass/volume] in Serum or Plasma | 9.1 | mg/dL | 3.5-7.2 mg/dL | High | S |
| 2026-03-02 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-02 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-02 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 25 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-03-02 | Urea nitrogen [Mass/volume] in Serum or Plasma | 22 | mg/dL | 8-23 mg/dL | Normal | S |
| 2026-03-02 | Creatinine [Mass/volume] in Serum or Plasma | 1.36 | mg/dL | 0.74-1.35 mg/dL | High | S |
| 2026-03-02 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 54 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 2026-03-02 | Glucose [Mass/volume] in Serum or Plasma | 98 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-03-02 | Calcium [Mass/volume] in Serum or Plasma | 9.5 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-03-02 | Phosphate [Mass/volume] in Serum or Plasma | 3.4 | mg/dL | 2.5-4.5 mg/dL | Normal | S |
| 2026-03-02 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 52 | pg/mL | 15-65 pg/mL | Normal | S |
| 2026-03-02 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 | ng/mL | 30-100 ng/mL | Normal | S |
| 2026-03-02 | Hemoglobin [Mass/volume] in Blood | 14.2 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-03-02 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-55 U/L | Normal | S |
| 2026-03-02 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 128 | mg/dL | <=99 mg/dL | High | S |
| 2026-03-02 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.6 | % | <=5.6% | Normal | S |
| 2026-03-02 | Albumin/Creatinine [Mass Ratio] in Urine | 18 | mg/g | <=30 mg/g | Normal | S |
| 2026-03-02 | pH of Urine | 5.2 | [pH] | 4.5-8 [pH] | Normal | S |
| 2026-03-02 | Erythrocytes [#/area] in Urine sediment by Microscopy high power field | 12 | /[HPF] | <=2 /[HPF] | High | S |
| 2026-03-02 | Lead [Mass/volume] in Blood | 3.1 | ug/dL | <=3.5 ug/dL | Normal | S |
| 2026-03-02 | International Prostate Symptom Score [IPSS] | 16 | {score} | S | ||
| 2026-03-02 | Kidney failure 2-year risk [Likelihood] by KFRE | 0.2 | % | S | ||
| 2026-03-02 | Kidney failure 5-year risk [Likelihood] by KFRE | 0.6 | % | S |